CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
22-116

APPROVAL LETTER
NDA 22-116

GlaxoSmithKline, Inc
ATTN: Eric B. Benson
Senior Director, US Regulatory Affairs
PO Box 13398
Five Moore Drive
Research Triangle Park, NC 27709

Dear Mr. Benson:

Please refer to your December 13, 2006, new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for LEXIVA® (fosamprenavir calcium; FPV) Oral Suspension.


This new drug application provides for the use of LEXIVA® (fosamprenavir calcium; FPV) Oral Suspension in combination with other antiretroviral agents for the treatment of HIV infection.

We completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

Within 21 days of the date of this letter, submit content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at http://www.fda.gov/oc/datacouncil/spl.html, that is identical in content to the enclosed submitted labeling dated June 14, 2007. Upon receipt, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission “SPL for approved NDA 22-116.”

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert, text for the patient package insert, immediate container and carton labels. Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit an electronic version of the FPL according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format - NDA. For administrative purposes, designate this submission “FPL for approved NDA 22-116.” Approval of this submission by FDA is not required before the labeling is used.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We are
NDA 22-116
Page 2

...tially waiving the pediatric study requirement for ages birth to one month and deferring pediatric studies for ages one month to two years for this application.

Your deferred pediatric study required under section 2 of the Pediatric Research Equity Act (PREA) is considered a required postmarketing study commitment. The status of this postmarketing study shall be reported annually according to 21 CFR 314.81. This commitment is listed below.

1. Deferred pediatric study under PREA for the treatment of HIV-1 in pediatric patients ages one month to two years.

   Final Report Submission: December 2009

Submit final study reports to this NDA. For administrative purposes, all submissions related to this pediatric postmarketing study commitment must be clearly designated “Required Pediatric Study Commitment”.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this division and two copies of both the promotional materials and the package insert directly to:

   Food and Drug Administration
   Center for Drug Evaluation and Research
   Division of Drug Marketing, Advertising, and Communications
   5901-B Ammendale Road
   Beltsville, MD 20705-1266

Please submit one market package of the drug product when it is available.

We have not completed validation of the regulatory methods. However, we expect your continued cooperation to resolve any problems that may be identified.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Marsha S. Holloman, BS Pharm, JD, Regulatory Health Project Manager at (301) 796-0731.

Sincerely,

[See appended electronic signature page]

Debra B. Birnkrant, MD
Director
Division of Antiviral Products (DAVP)
Office of Antimicrobial Products (OAP)
Center for Drug Evaluation and Research

Enclosure: Final Agreed-upon Labeling (Package Insert and Patient Package Insert)
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

-----------------------
Jeffrey Murray
6/14/2007 05:45:54 PM